‘Off-the-shelf’ allogeneic CAR T cells: development and challenges

[1]  C. Mackall,et al.  Clinical lessons learned from the first leg of the CAR T cell journey , 2019, Nature Medicine.

[2]  Jeremy D. Goldhaber-Fiebert,et al.  Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Orentas,et al.  CD19 CAR T cell product and disease attributes predict leukemia remission durability. , 2019, The Journal of clinical investigation.

[4]  T. Mahmood,et al.  CRISPR/Cas system: A game changing genome editing technology, to treat human genetic diseases. , 2019, Gene.

[5]  Q. Liao,et al.  CRISPR-Cpf1-mediated genome editing and gene regulation in human cells. , 2019, Biotechnology advances.

[6]  Waseem Qasim,et al.  Preliminary Data on Safety, Cellular Kinetics and Anti-Leukemic Activity of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a Pool of Adult and Pediatric Patients with High-Risk CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia , 2018, Blood.

[7]  C. Kachramanoglou,et al.  Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting , 2018, Cancer cell.

[8]  T. Reya,et al.  Stem cell fate in cancer growth, progression and therapy resistance , 2018, Nature Reviews Cancer.

[9]  Waseem Qasim,et al.  TCRαβ/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy. , 2018, JCI insight.

[10]  V. Seshan,et al.  Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo , 2018, Nature Biotechnology.

[11]  C. June,et al.  Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  S. Riddell,et al.  Chimeric antigen receptor-modified T cells: CD19 and the road beyond. , 2018, Blood.

[13]  W. Fisher,et al.  Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. , 2018, Cancer discovery.

[14]  Avery D Posey,et al.  Driving cars to the clinic for solid tumors , 2018, Gene Therapy.

[15]  Paul Chamberlain,et al.  Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy – Moving Target for Industry? , 2018, Pharmaceutical Research.

[16]  Tyler J. Reich,et al.  Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells , 2018, Nature.

[17]  R. V. van Lier,et al.  Tissue-resident memory T cells at the center of immunity to solid tumors , 2018, Nature Immunology.

[18]  M. Spitzer,et al.  Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System , 2018, Cell reports.

[19]  B. Jakobsen,et al.  Fludarabine and neurotoxicity in engineered T-cell therapy , 2018, Gene Therapy.

[20]  D. Tscharke,et al.  Tissue‐resident memory T cells in tissue homeostasis, persistent infection, and cancer surveillance , 2018, Immunological reviews.

[21]  H. Abken,et al.  CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications. , 2018, Human gene therapy.

[22]  D. Blaise,et al.  The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation , 2018, Bone Marrow Transplantation.

[23]  Hans Bitter,et al.  Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia , 2018, Nature Medicine.

[24]  T. Schumacher,et al.  T Cell Dysfunction in Cancer. , 2018, Cancer cell.

[25]  Theresa Kaeuferle,et al.  Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia , 2018, Cancer Immunology, Immunotherapy.

[26]  Omkar U. Kawalekar,et al.  CAR T cell immunotherapy for human cancer , 2018, Science.

[27]  J. Borghans,et al.  The full spectrum of human naive T cells , 2018, Nature Reviews Immunology.

[28]  B. Sacchetti,et al.  CAR-T cells: the long and winding road to solid tumors , 2018, Cell Death & Disease.

[29]  Katayoun Rezvani,et al.  Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer , 2018, Front. Immunol..

[30]  J. Orange,et al.  Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity , 2018, Leukemia.

[31]  Mithat Gonen,et al.  Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[32]  K. Davis,et al.  Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[33]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[34]  Hanmei Xu,et al.  Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors , 2018, Molecular Cancer.

[35]  Brian Keith,et al.  Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. , 2018, JCI insight.

[36]  R. Blasczyk,et al.  Cord blood–derived T cells allow the generation of a more naïve tumor‐reactive cytotoxic T‐cell phenotype , 2018, Transfusion.

[37]  K. Gustafsson,et al.  Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  R. Galetto,et al.  Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia , 2016, Leukemia & lymphoma.

[39]  M. Jasin,et al.  Induction of Chromosomal Translocations with CRISPR-Cas9 and Other Nucleases: Understanding the Repair Mechanisms That Give Rise to Translocations. , 2018, Advances in experimental medicine and biology.

[40]  Yang Feng,et al.  CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL , 2017, Nature Medicine.

[41]  B. Badie,et al.  Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications , 2017, Front. Immunol..

[42]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[43]  B. Blazar,et al.  Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. , 2017, The New England journal of medicine.

[44]  Daniel Li,et al.  Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. , 2017, Blood.

[45]  Ying Hu,et al.  TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance , 2017, Science Translational Medicine.

[46]  D. Dimitrov,et al.  CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL , 2017, Nature medicine.

[47]  H. Goossens,et al.  Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. , 2017, Blood.

[48]  T. Maeda,et al.  NK Cell Alloreactivity against KIR-Ligand-Mismatched HLA-Haploidentical Tissue Derived from HLA Haplotype-Homozygous iPSCs , 2017, Stem cell reports.

[49]  H. Abdel-Azim,et al.  Role of αβ T Cell Depletion in Prevention of Graft versus Host Disease , 2017, Biomedicines.

[50]  M. Pogson,et al.  Crystallographic analyses illustrate significant plasticity and efficient recoding of meganuclease target specificity , 2017, Nucleic acids research.

[51]  Hao Liu,et al.  Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants , 2017, Cancer Immunology Research.

[52]  D. Clegg,et al.  HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells , 2017, Nature Biotechnology.

[53]  M. Mohty,et al.  Pre-transplant donor CD4− invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease , 2017, Leukemia.

[54]  Kimberly A. Thomas,et al.  Not All Antibodies Are Created Equal: Factors That Influence Antibody Mediated Rejection , 2017, Journal of immunology research.

[55]  Mithat Gönen,et al.  Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection , 2017, Nature.

[56]  Aaron J. Martin,et al.  Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[57]  Carl H. June,et al.  A versatile system for rapid multiplex genome-edited CAR T cell generation , 2017, Oncotarget.

[58]  B. Dörken,et al.  Predictive significance of the European LeukemiaNet classification of genetic aberrations in patients with acute myeloid leukaemia undergoing allogeneic stem cell transplantation , 2017, European journal of haematology.

[59]  Adrian J. Thrasher,et al.  Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells , 2017, Science Translational Medicine.

[60]  Alan Maréchal,et al.  An oxygen sensitive self-decision making engineered CAR T-cell , 2017, Scientific Reports.

[61]  A. Scharenberg,et al.  Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T Cells , 2017, Molecular therapy. Methods & clinical development.

[62]  P. Mathew,et al.  CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma. , 2017, American journal of cancer research.

[63]  V. Appay,et al.  Human Stem Cell-like Memory T Cells Are Maintained in a State of Dynamic Flux , 2016, Cell reports.

[64]  Burton E. Barnett,et al.  piggyBacTM-Produced CAR-T Cells Exhibit Stem-Cell Memory Phenotype , 2016 .

[65]  M. Mann,et al.  L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity , 2016, Cell.

[66]  S. Rosenberg,et al.  Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Yang Feng,et al.  Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. , 2016, The Journal of clinical investigation.

[68]  M. Richer,et al.  Regulation of effector and memory CD8(+) T cell function by inflammatory cytokines. , 2016, Cytokine.

[69]  Renier J. Brentjens,et al.  Driving CAR T-cells forward , 2016, Nature Reviews Clinical Oncology.

[70]  C. June,et al.  Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy , 2016, Clinical Cancer Research.

[71]  R. O'reilly,et al.  Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections , 2016, Bone Marrow Transplantation.

[72]  C. June,et al.  A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. , 2016, Cancer research.

[73]  Christof von Kalle,et al.  Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[74]  D. Maloney,et al.  Accepted Article Preview : Published ahead of advance online publication , 2016 .

[75]  V. Buchholz,et al.  Role of memory T cell subsets for adoptive immunotherapy. , 2016, Seminars in immunology.

[76]  Peter Bader,et al.  Selection and expansion of natural killer cells for NK cell-based immunotherapy , 2016, Cancer Immunology, Immunotherapy.

[77]  D. Mougiakakos,et al.  Coexpressed Catalase Protects Chimeric Antigen Receptor–Redirected T Cells as well as Bystander Cells from Oxidative Stress–Induced Loss of Antitumor Activity , 2016, The Journal of Immunology.

[78]  Ciaran M Lee,et al.  Nuclease Target Site Selection for Maximizing On-target Activity and Minimizing Off-target Effects in Genome Editing , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[79]  D. Maloney,et al.  Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo , 2015, Leukemia.

[80]  Fadi G Lakkis,et al.  Memory T Cell Migration , 2015, Front. Immunol..

[81]  Y. Quan,et al.  Targeted Disruption of the β2‐Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells , 2015, Stem cells translational medicine.

[82]  Aymeric Duclert,et al.  Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies. , 2015, Cancer research.

[83]  M. Caligiuri,et al.  CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells , 2015, Scientific Reports.

[84]  Alan Maréchal,et al.  A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[85]  A. Tosti,et al.  Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality. , 2015, Blood.

[86]  Michel Sadelain,et al.  New cell sources for T cell engineering and adoptive immunotherapy. , 2015, Cell stem cell.

[87]  Eugene S. Kim,et al.  Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T-lymphocytes , 2015, Nature Medicine.

[88]  R. Luong,et al.  CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells. , 2014, Blood.

[89]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[90]  S. Thunberg,et al.  Alpha/Beta T-Cell Depleted Grafts as an Immunological Booster to Treat Graft Failure after Hematopoietic Stem Cell Transplantation with HLA-Matched Related and Unrelated Donors , 2014, Journal of immunology research.

[91]  James E Haber,et al.  Sources of DNA double-strand breaks and models of recombinational DNA repair. , 2014, Cold Spring Harbor perspectives in biology.

[92]  Mikhail Zaslavskiy,et al.  Efficient design of meganucleases using a machine learning approach , 2014, BMC Bioinformatics.

[93]  C. Creighton,et al.  Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. , 2014, Blood.

[94]  G. Ehninger,et al.  Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia , 2014, Blood Cancer Journal.

[95]  P. Romero,et al.  Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. , 2014, The Journal of clinical investigation.

[96]  M. Essand,et al.  Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors , 2014, Molecular therapy. Methods & clinical development.

[97]  David Baker,et al.  megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering , 2013, Nucleic acids research.

[98]  M. Caligiuri,et al.  CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered Natural Killer Cells Enhance In Vitro and In Vivo Anti-tumor Activity Against Human Multiple Myeloma , 2013, Leukemia.

[99]  B. Kahn-Perlès,et al.  Natural Killer Cells Modulation in Hematological Malignancies , 2013, Front. Immunol..

[100]  Sadik H. Kassim,et al.  Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. , 2013, Blood.

[101]  Erin L. Doyle,et al.  TAL Effector Specificity for base 0 of the DNA Target Is Altered in a Complex, Effector- and Assay-Dependent Manner by Substitutions for the Tryptophan in Cryptic Repeat –1 , 2013, PloS one.

[102]  E. Seifried,et al.  Treatment of patients with advanced cancer with the natural killer cell line NK-92. , 2013, Cytotherapy.

[103]  C. Cruz,et al.  Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. , 2013, Blood.

[104]  H. Einsele,et al.  Alloreactivity of Virus-Specific T Cells: Possible Implication of Graft-Versus-Host Disease and Graft-Versus-Leukemia Effects , 2013, Front. Immunol..

[105]  Mithat Gonen,et al.  Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy , 2013, Nature Biotechnology.

[106]  A. Iwasaki,et al.  Tissue‐resident memory T cells , 2013, Immunological reviews.

[107]  S. Pai,et al.  Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. , 2013, Blood.

[108]  J. Keith Joung,et al.  High frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells , 2013, Nature Biotechnology.

[109]  S. Rosenberg,et al.  Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors , 2013, Nature Reviews Clinical Oncology.

[110]  T. E. Wilson,et al.  Repair of double-strand breaks by end joining. , 2013, Cold Spring Harbor perspectives in biology.

[111]  M. Yarmush,et al.  Characterization and ex vivo Expansion of Human Placenta-Derived Natural Killer Cells for Cancer Immunotherapy , 2013, Front. Immunol..

[112]  Daniel F. Voytas,et al.  Compact designer TALENs for efficient genome engineering , 2013, Nature Communications.

[113]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[114]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[115]  S. Bicciato,et al.  IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. , 2013, Blood.

[116]  R. Korngold,et al.  Unraveling Graft-versus-Host Disease and Graft-versus-Leukemia Responses Using TCR Vβ Spectratype Analysis in a Murine Bone Marrow Transplantation Model , 2013, The Journal of Immunology.

[117]  J. Bradley,et al.  Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. , 2012, Cell stem cell.

[118]  Luigi Naldini,et al.  A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. , 2012, Blood.

[119]  S. Steinberg,et al.  Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. , 2012, Blood.

[120]  D. Marin,et al.  Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. , 2012, Blood.

[121]  J. Bromberg.  Implications for transplantation , 2012 .

[122]  N. Tchao,et al.  Lymphodepletion and Homeostatic Proliferation: Implications for Transplantation , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[123]  A. Blaschitz,et al.  HLA class I expression in the human placenta , 2012, Wiener Medizinische Wochenschrift.

[124]  N. K. Tchaoa,et al.  Lymphodepletion and Homeostatic Proliferation : Implications for Transplantation , 2012 .

[125]  Martin Pule,et al.  Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. , 2011, Blood.

[126]  F. Marincola,et al.  A human memory T-cell subset with stem cell-like properties , 2011, Nature Medicine.

[127]  Jing Sun,et al.  Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor , 2011, Clinical Cancer Research.

[128]  Erin L. Doyle,et al.  Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting , 2011, Nucleic acids research.

[129]  S. Rosenberg,et al.  Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[130]  R. Luong,et al.  Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism. , 2011, Blood.

[131]  J. Melenhorst,et al.  Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. , 2010, Blood.

[132]  C. Rooney,et al.  Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b , 2010, Journal of immunotherapy.

[133]  C. Liu,et al.  Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses , 2010, Clinical Cancer Research.

[134]  E. Rebar,et al.  Genome editing with engineered zinc finger nucleases , 2010, Nature Reviews Genetics.

[135]  J. Wagner,et al.  Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. , 2010, The Lancet. Oncology.

[136]  Robert E. Hawkins,et al.  The Optimal Antigen Response of Chimeric Antigen Receptors Harboring the CD3ζ Transmembrane Domain Is Dependent upon Incorporation of the Receptor into the Endogenous TCR/CD3 Complex , 2010, The Journal of Immunology.

[137]  Rachel J. Johnson,et al.  Factors Influencing Outcome After Deceased Heart Beating Donor Kidney Transplantation in the United Kingdom: An Evidence Base for a New National Kidney Allocation Policy , 2010, Transplantation.

[138]  J. Mönkkönen,et al.  Activation of γδ T cells by bisphosphonates. , 2010, Advances in experimental medicine and biology.

[139]  Jens Boch,et al.  Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors , 2009, Science.

[140]  Matthew J. Moscou,et al.  A Simple Cipher Governs DNA Recognition by TAL Effectors , 2009, Science.

[141]  M. Tan,et al.  Rapid Immune Recovery and Graft-versus-Host Disease–like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells , 2009, Clinical Cancer Research.

[142]  I. Pastan,et al.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains , 2009, Proceedings of the National Academy of Sciences.

[143]  M. Okada,et al.  Induction of γδT Cells Using Zoledronate Plus Interleukin-2 in Patients with Metastatic Cancer , 2009 .

[144]  M. Okada,et al.  Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer. , 2009, Hiroshima journal of medical sciences.

[145]  S. Feig,et al.  Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. , 2008, Blood.

[146]  Anis Larbi,et al.  Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people , 2008, Immunity & Ageing.

[147]  Mike Gough,et al.  Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. , 2008, The Journal of clinical investigation.

[148]  Paul M. Allen,et al.  Specificity of T-cell alloreactivity , 2007, Nature Reviews Immunology.

[149]  Gerhard Opelz,et al.  Effect of Human Leukocyte Antigen Compatibility on Kidney Graft Survival: Comparative Analysis of Two Decades , 2007, Transplantation.

[150]  Michelle M. Sandau,et al.  IL-15 Is Required for Sustained Lymphopenia-Driven Proliferation and Accumulation of CD8 T Cells1 , 2007, The Journal of Immunology.

[151]  Daniel Olive,et al.  Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. , 2007, Blood.

[152]  S. Rosenberg,et al.  Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go? , 2006, Nature Clinical Practice Oncology.

[153]  T. Lister,et al.  Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. , 2005, Blood.

[154]  W. Blackwelder,et al.  Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer , 2005, Nature Medicine.

[155]  Dana Carroll,et al.  Gene targeting using zinc finger nucleases , 2005, Nature Biotechnology.

[156]  P. Bucher,et al.  Long Distance Control of MHC Class II Expression by Multiple Distal Enhancers Regulated by Regulatory Factor X Complex and CIITA1 , 2004, The Journal of Immunology.

[157]  Antonio Lanzavecchia,et al.  Central memory and effector memory T cell subsets: function, generation, and maintenance. , 2004, Annual review of immunology.

[158]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[159]  D. Olive,et al.  Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. , 2002, Blood.

[160]  P. J. van den Elsen,et al.  Activated Human T Cells Accomplish MHC Class II Expression Through T Cell-Specific Occupation of Class II Transactivator Promoter III1 , 2002, The Journal of Immunology.

[161]  Yoshimasa Tanaka,et al.  Targeting of Tumor Cells for Human γδ T Cells by Nonpeptide Antigens1 , 2001, The Journal of Immunology.

[162]  M. Lederman,et al.  A potential role for interleukin-7 in T-cell homeostasis. , 2001, Blood.

[163]  N. Minato,et al.  Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens. , 2001, Journal of immunology.

[164]  J. Klein,et al.  T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. , 2000, Blood.

[165]  A. Chott,et al.  CD1d structure and regulation on human thymocytes, peripheral blood T cells,B cells and monocytes , 2000, Immunology.

[166]  J. Jacobberger,et al.  Reduced NFAT1 protein expression in human umbilical cord blood T lymphocytes. , 1999, Blood.

[167]  S. Porcelli,et al.  Response of murine and normal human skin to injection of allogeneic blood-derived psoriatic immunocytes: detection of T cells expressing receptors typically present on natural killer cells, including CD94, CD158, and CD161. , 1999, Archives of Dermatology.

[168]  E. Podack,et al.  The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice , 1996, The Journal of experimental medicine.

[169]  S Chandrasegaran,et al.  Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[170]  B. Dujon,et al.  Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of Saccharomyces cerevisiae , 1995, Molecular and cellular biology.

[171]  P. Rouet,et al.  Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. , 1994, Molecular and cellular biology.

[172]  M. F. Parry,et al.  A Retrospective Analysis , 1990 .

[173]  H. Waldmann,et al.  T cell depletion of human bone marrow. Comparison of Campath-1 plus complement, anti-T cell ricin A chain immunotoxin, and soybean agglutinin alone or in combination with sheep erythrocytes or immunomagnetic beads. , 1989, Transplantation.

[174]  Prentice Hg.  OKT3 incubation of donor marrow for prophylaxis of acute graft-vs.-host disease (GvHD) in allogeneic bone marrow transplantation. , 1982 .

[175]  J. Ochoa,et al.  T Lymphocytes , 1982, The Lancet.

[176]  H. Prentice.  OKT3 incubation of donor marrow for prophylaxis of acute graft-vs.-host disease (GvHD) in allogeneic bone marrow transplantation. , 1982, Journal of clinical immunology.